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MECHANISMS THAT REGULATE PRO-INFLAMMATORY CYTOKINE 
EXPRESSION IN CD4+ T CELLS 
TROY SANDERS 
ABSTRACT 
Cytokines released by innate immune cells initiate pathways that drive the differentiation 
of CD4+ T cells into subsets with defined patterns of cytokine secretion. Type I 
interferons (IFNs) are cytokines that decrease a virus’s capability to replicate in cells. 
Prolonged exposure to them, as in chronic viral infections, lead to immune suppression. 
Little is known about the effects of type I IFNs on cytokine expression by CD4+ T cells. 
My studies, as described in this thesis, show that the type I IFN, IFN can impact 
cytokine secretion by CD4+ T cells, and timing of IFNα exposure can impact the effect. 
When isolated mouse CD4+ T cells were pre-treated with IFNα prior to activation, 
expression of the gene encoding Interleukin-2 (IL-2) significantly increased and 
expression of the gene encoding IFNγ significantly decreased. When T cell Receptor 
(TCR) and type I IFN pathways were activated simultaneously, expression of the gene 
encoding Granulocyte-macrophage colony-stimulating factor (GM-CSF) was decreased. 
Since timing of IFNα exposure changed the effect, these results demonstrate the 
sensitivity of the interconnections between the IFNα pathway and pro-inflammatory 
cytokine expression pathway. These results indicate altered cytokine expression due to 
prolonged exposure of CD4+ T cells to IFNα as a possible explanation for immune 
suppression in chronic viral infection. Ikaros is a transcription factor that regulates 
expression of some pro-inflammatory cytokines. CD4+ T cells that lacked Ikaros 
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expression responded differently to IFNα exposure indicating a possible role for Ikaros in 
modulating the effect of IFNα on the expression of pro-inflammatory cytokines.   
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INTRODUCTION 
T Lymphocytes in the Adaptive Immune Response 
 A functional and regulated immune response to pathogens is necessary for human 
health. The immune system is the body’s way of fighting off foreign invaders. An 
overactive immune system can result in diseases such as rheumatoid arthritis, celiac 
disease, multiple sclerosis, and Graves’ disease by maintaining an excessive 
inflammatory response. Short-term inflammation is an effective tool to allow infiltration 
of immune cells into sites of infection from the bloodstream which then fight off foreign 
invaders and signal other immune cells to the scene for a holistic treatment of the 
infection (Medzhitov, 2010). T lymphocytes are one of these families of cells. T 
lymphocytes can have direct cytotoxic effects and regulate the immune response of other 
cells.  
 There are two main categories of αβ T lymphocytes: CD4+ T cells and CD8+ T 
cells. CD4+ T cells are called helper T cells (Th) because they help other cells of the 
immune system perform their role in the immune response (Vignali, Collison, & 
Workman, 2008). They regulate inflammation via secretion of cytokines that promote 
chemotaxis of neutrophils, secretion of isotype-switched antibodies by B cells, 
differentiation of T cells, and activation of the microbicidal effects of macrophages. The 
role of CD8+ T cells or cytotoxic T lymphocytes (CTLs) is to kill infected cells by 
releasing cytotoxic proteins including granzymes and perforin. This function can only be 
achieved if activated Th cells release cytokines activating the CTL (Bennett et al., 1998).  
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There are different subsets of Th cells which are tailored to respond differently 
depending on the pathogen. Signals from pathogens delivered via various receptors such 
as toll like receptors (TLRs) or C-type lectin receptors along with changes to the cell’s 
environment induce expression of specific transcription factors that cause alterations to a 
naïve CD4+ cell’s gene expression program (Bermejo-Jambrina et al., 2018; Gelman, 
Zhang, Choi, & Turka, 2004). These changes direct the cell to differentiate into a Th cell 
that can mount the most effective response against the pathogen providing the signals 
(Hsieh, Heimberger, Gold, O’Garra, & Murphy, 1992). 
An effective adaptive immune response is only possible with the help of CD4+ T 
cells. CD4+ T cells release chemical signals called cytokines which signal the immune 
response to react in a way that is catered to the invading microbe. Antigen presenting 
cells (APCs) present processed antigen via major histocompatibility complex class II 
(MHC II) to the TCR of CD4+ T cells. The presented antigen along with cytokines 
largely secreted by innate immune cells present in the cell’s microenvironment drive 
differentiation into a specific Th cell subset. There are four main CD4+ T cell subsets of 
interest in this thesis: T helper cell type 1 (Th1), T helper cell type 2 (Th2), regulatory T 
cells (Tregs), and T helper 17 cells (Th17). Each category of CD4+ T cell is responsible 
for influencing immune cells to appropriately and effectively combat specific types of 
infections. 
Cytokines Instruct the T cell Response 
Cytokines act as chemical messengers in the immune system that direct immune 
cells in their response to a pathogenic assault. Th cells differentiate into cell subsets 
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which release a particular cytokine profile. Th1 cells differentiate in response to IL-12 
present in the microenvironment of the activated CD4+ T cell. IL-12 signaling leads to 
expression and activation of transcription factors T-bet and STAT1, respectively. This 
programs cells to release high levels of IFN-γ, Tumor Necrosis Factor α (TNFα), and IL-
2 in response to TCR signaling. These cytokines 1) activate macrophages through the 
classic pathway into an M1 phenotype that destroys intracellular pathogens, 2) act as 
secondary signals necessary for activating CD8+ T cell responses, and 3) induce release 
of chemokines that lead to chemotaxis of inflammatory leukocytes which cause tissue 
damage and inflammation. (Martinez & Gordon, 2014) 
Th2 cells differentiate in the presence of IL-4. IL-4 signaling causes the activated 
CD4+ T cell to upregulate the expression of GATA-3 and activate STAT6 by 
phosphorylation, which drives the cell’s differentiation (Maier, Duschl, & Horejs-Hoeck, 
2012). Th2 cells release IL-4, IL-5 and IL-13, which help the body fight helminthic 
infections while also promoting tissue repair following resolution of an infection (Walker 
& McKenzie, 2018). A polarized Th2 response also instructs macrophages to activate 
through the alternative pathway leading to the M2 phenotype, which promotes tissue 
repair by inhibiting inflammation. 
CD4+ T cells differentiate into Th17 cells in the presence of Transforming 
Growth Factor β (TGFβ), IL-1, IL-6, and IL-23. The combination of these cytokines 
causes the activated CD4+ T cell to upregulate the expression of transcription factor 
RORγt and to activate the transcription factor STAT3 via phosphorylation (Yang et al., 
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2007). Th17 cells release IL-17 and help eliminate extracellular bacterial and fungal 
infections frequently at mucosal surfaces (Korn et al., 2007).  
The regulatory T cell (Treg) differentiates in the thymus or peripheral tissues 
upon recognition of self-antigen. Peripherally derived or inducible Tregs (iTreg cells) 
differentiate from CD4+ T cells that are activated in the presence of IL-2 and TGFβ 
(Chen et al., 2003). TGFβ upregulates FoxP3 and IL-2 is required for survival and 
expansion of iTregs. iTreg cells suppress the activation of CD4+ T cells by releasing 
cytokines that shut off or dampen immune responses. The role of Treg cells is to limit the 
immune response of other Th cells such as Th1 or Th17 cells whose cytokines are 
directly involved in the inflammatory response  (Christie & Zhu, 2014). Too much 
inflammation caused by unregulated release of pro-inflammatory cytokines from these 
cells such as IL-1 or IFNγ can lead to autoimmune or inflammatory diseases (Lourenço & 
Cava, 2009).  
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Figure 1. Th cell differentiation. This figure shows cytokines necessary to differentiate 
an antigen-activated CD4+ T cell into the above subsets of Th cell. Below each cell 
subset are the different transcription factors that are activated or whose expression is 
increased when exposed to the differentiation cytokine leading to the particular subset. 
(Maier et al., 2012; Shevach & Thornton, 2014; Thieu et al., 2008; Yang et al., 2007) 
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Ikaros in T cells 
Differentiation of Th subsets relies on transcriptional changes involving 
transcription factors that initiate these transitions in gene expression. The DNA binding 
protein Ikaros is one such factor. Ikaros is essential to proper development and 
differentiation of CD4+ T lymphocytes in the thymus (Urban, Brugmann, & Winandy, 
2009; Urban & Winandy, 2004; Wang et al., 1996). Ikaros has been shown to be a tumor 
suppressor during lymphocyte development (Kathrein, Lorenz, Innes, Griffiths, & 
Winandy, 2005). Without Ikaros, mice developed T cell leukemia within 5 weeks of age 
with 100% penetrance (Wang et al., 1996). Mature CD4+ T cells lacking Ikaros are able 
to differentiate into Th1, Th2, and Th17 cells, but not iTregs (Lyon de Ana, Arakcheeva, 
Agnihotri, Derosia, & Winandy, 2019). These cells also show enhanced expression of 
proinflammatory cytokines that are associated with pathological inflammation and 
autoimmunity. Ikaros has also been identified as a suppressor of the response to type I 
IFNs (Lyon de Ana et al., 2019). 
Previous knockout models of Ikaros deleted Ikaros expression at the level of the 
germline. While this depicted the importance of its expression from the level of the 
Hematopoietic Stem Cell (HSC), the knockout model’s deleterious effects prevented 
observation of its importance in mature T cell differentiation. Dr. Susan Winandy with 
the help of the Mouse Biology Program at University of California, Davis developed a 
conditional knockout mouse that can be used to knock out Ikaros expression in the 
mature T cell (Lyon de Ana et al., 2019). The method used involves placement of loxP 
sites that flox the most important exon of the Ikaros gene (Ikzf1), exon 7. Exon 7 contains 
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the activation domain and a dimerization domain and its deletion leads to the inability to 
express a protein (Georgopoulos, Winandy, & Avitahl, 1997). The exon’s deletion is 
induced by expression of Cre-recombinase whose expression was driven by the distal Lck 
promoter. Lck is a tyrosine kinase whose distal promoter of its gene is only expressed in 
mature T lymphocytes (Hernández-Hoyos, Sohn, Rothenberg, & Alberola-Ila, 2000). Due 
to this characteristic the Cre-recombinase expression only occurs in mature T 
lymphocytes. When exon 7 is deleted, the mRNA becomes unstable and as a result does 
not get translated into a protein (Lyon de Ana et al., 2019). Deletion of other exons often 
results in a mutant Ikaros protein that avoids complete loss of expression via alternative 
splicing (Vshyukova, Valochnik, & Meleshko, 2018). In this thesis, the cells that have 
Cre-recombinase and thus lack Ikaros will be called Cre+ cells. Those without Cre-
recombinase who therefore have normal levels of Ikaros will be called Cre- cells.  
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Figure 2: Schematic Representation of Floxed Ikzf1 Locus in Ikflox mice. 
The Ikzf1 gene encodes the transcription factor that contains five zinc-finger motifs called 
Ikaros. This model which is not to scale shows how loxP sites were placed on either side 
of exon 7 making it floxed and allowed for induction of the exon’s deletion upon 
expression of Cre-recombinase. By breeding this mouse with an Lck-distal promoter-Cre-
recombinase transgenic mouse, exon 7 is only deleted in T cells.  
UTR = Untranslated Region 
Modified from (Lyon de Ana et al., 2019). 
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The Functional Role of T cell-derived Cytokines in the Immune Response 
Recent studies have revealed a role for Ikaros in regulating expression of 
cytokines in T cells. There are many cytokines secreted by T cells that are important to 
the immune response, but one especially unique cytokine is IL-2. IL-2 acts 
dichotomously: it acts to stimulate activated T cell proliferation and it acts to support the 
production of Tregs (Setoguchi, Hori, Takahashi, & Sakaguchi, 2005). All Tregs express 
CD25 which is the high affinity α chain of the IL-2 receptor (Nelson, 2004). CD25 
expression on Tregs is extremely important for their function in down-regulating 
inflammation. In a case of a human with a truncation mutation of CD25, unregulated 
proliferation of T cells and extensive lymphocyte penetration in various tissues occurred. 
This resulted in severe tissue atrophy and inflammation which illustrates the importance 
of CD25 and IL-2 in their function (Roifman, 2000). By having a role in supporting Treg 
generation, IL-2 acts to ensure the immune system is self-limiting leading to decreased 
inflammation and damage. Following TCR stimulation/co-stimulation with anti-CD3 and 
anti-CD28, respectively, Cre+ CD4+ T cells show increased IL-2 expression relative to 
that observed for Cre- CD4+ T cells (Lyon de Ana et al., 2019). 
IFNγ is another cytokine that can be secreted by CD4+ T cells. Signals provided 
by IFNγ lead to the killing of a phagocytosed microbe and inflammation. In excess, IFNγ 
can cause autoimmune diseases and chronic inflammation (Hu & Ivashkiv, 2009). 
Following TCR stimulation/co-stimulation, Cre+ CD4+ T cells show increased IFNγ 
expression relative to that observed for Cre- CD4+ T cells (Lyon de Ana et al., 2019). 
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GM-CSF is an inflammatory cytokine whose primary role is to participate in the 
differentiation of granulocyte and macrophage populations. GM-CSF has been found at 
higher levels in autoimmune diseases like rheumatoid arthritis and multiple sclerosis 
(Bhattacharya et al., 2015). Following TCR stimulation/co-stimulation, Cre+ CD4+ T 
cells show increased GM-CSF expression relative to that observed for Cre- CD4+ T cells 
(Lyon de Ana et al., 2019). 
TNFα is a cytokine that plays a role in chronic inflammation. It is produced 
primarily by macrophages, but is made by many cell types including T cells (Kalliolias & 
Ivashkiv, 2016). When TNFα interacts with endothelial cells, the cells loosen their 
adhesion to each other making blood vessels permeable to immune cells allowing them to 
exit the circulation and travel to the site of injury or infection. TNF-α is also known as an 
endogenous pyrogen and has an anorexigenic effect when it interacts with the 
hypothalamus (Romanatto et al., 2007). It also can cause apoptosis in many cell types. 
Following TCR stimulation/co-stimulation, Cre+ CD4+ T cells show increased TNF-α 
expression relative to that observed for Cre- CD4+ T cells (Lyon de Ana et al., 2019). 
IL-4 is a cytokine released by activated CD4+ Th2 cells, mast cells and basophils 
(Gadani, Cronk, Norris, & Kipnis, 2012). It induces isotype switching to IgE in B cells 
and is important in atopic disease induction and maintenance (Fiset, Cameron, & Hamid, 
2005). There is no significant difference in expression of IL-4 in CD4+ T cells that lack 
Ikaros compared to those with normal Ikaros expression (Lyon de Ana et al., 2019). This 
showed that lack of Ikaros does not impact expression of all cytokines. 
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Type I Interferon Response 
 Type I IFNs are a group of cytokines responsible for inhibiting virus replication 
by influencing the development of innate and adaptive immune responses. IFNα is an 
important type I IFN of the immune response (Fensterl, Chattopadhyay, & Sen, 2015). 
When bound to the interferon alpha/beta receptor (IFNAR), IFNα and IFNβ will induce 
expression of hundreds of genes known as interferon stimulated genes (ISG) (Fensterl et 
al., 2015). IFNAR engagement by IFNα causes activation of protein tyrosine kinase Janus 
kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) (Hervas-Stubbs et al., 2011). These 
proteins then phosphorylate intracellular domains of the IFNAR which provides sites of 
recruitment for proteins STAT1 and STAT2 at the SH2 domains (Au-Yeung, Mandhana, 
& Horvath, 2013). Once activated via phosphorylation, the STAT proteins dimerize and 
move to the nucleus of the cell. When there, these proteins associate with IFN regulatory 
factor 9 (IRF9) forming the transcription factor complex called ISGF3, which then results 
in increased transcription of ISGs by binding the IFN-stimulated response element (Au-
Yeung et al., 2013). Expression of ISGs activates a cell’s Type I IFN-induced antiviral 
mechanisms and promotes inflammation. A sustained state of inflammation can lead to a 
more significant and serious disease progression in chronic infections. Type I IFNs are 
key players in this sustained inflammatory state such as during the progression of the 
simian immunodeficiency virus (SIV) to Simian Autoimmune Deficiency Syndrome 
(SAIDS) (Harris et al., 2010). 
 Chronic viral infections contain seemingly mutually exclusive immune states of 
both inflammation and immunosuppression. The linkage between these two states allows 
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the immune response to avoid excessive responses to pathogens once they are controlled 
but can also lead to immune system dysfunction. Type I IFNs are an important factor in 
inducing inflammation and activating factors that play a role in suppressing the immune 
response.  
 All infected cells are capable of producing type I IFNs (Kolumam, Thomas, 
Thompson, Sprent, & Murali-Krishna, 2005). With chronic infections, the inability to 
clear virus leads to the progressive dysfunction of CD8+ T cells causing them to be 
significantly less effective but still maintain limited viral control. This is known as T cell 
exhaustion (Moskophidis, Lechner, Pircher, & Zinkernagel, 1993). With initial viral 
infection, Type I IFNs signal CD8+ T cells to expand and activate the cytolytic function 
of CTLs (Kolumam et al., 2005; Wiesel et al., 2012). During chronic viral infections, 
Type I IFNs cause a state of immune dysfunction caused in part by their ability to drive 
formation of a CD8+ T cell subset that has enhanced cytotoxic functionality but cannot 
renew itself which leads to viral persistence (Teijaro et al., 2013).  
During the onset of persistent viral infection, CD4+ T cells favor differentiation 
into Th1 cells which help CD8+ T cells destroy virally infected cells (Osokine et al., 
2014). However, viral persistence and constant TCR stimulation drives transformation of 
virus-specific Th1 cells into T follicular helper cells (Tfh) (Osokine et al., 2014). With 
Tfh cell differentiation favored over Th1 cell differentiation, CD4+ T cells primed to the 
persistent viral infection provide help to B cells, but limited help to CD8+ T cells. This 
limitation in differentiation to the Th1 subset was found to be mediated by Type I IFN 
production (Osokine et al., 2014). The limitation of differentiation to a Th1 subset 
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mediated by Type I IFNs is also observed in chronic viral infections such as Human 
Immunodeficiency Virus (HIV), SIV, and Hepatitis C Virus (HCV) (Feng et al., 2012; 
Lindqvist et al., 2012; Petrovas et al., 2012). These various effects of the type I IFN 
response highlight the complex role type I IFNs play in antiviral responses. 
By changing the favored CD4+ T cell subset to Tfh, this could also change the 
cytokine profile seen in a chronic viral infection. Tfh cells are a specialized subset of 
CD4+ T cells found within germinal centers of lymphoid organs. The cytokines they 
primarily produce enhance B cell responses and include IL-21 and IL-4 (Varricchi et al., 
2016). Th1 cells on the other hand produce IL-2, TNF-β and IFNγ, which are pro-
inflammatory cytokines (Martinez & Gordon, 2014).  
Much has been discovered about how cytokines induced by microbes affect the T 
cell response, but not much is known about the effect of type I IFNs on T cells’ 
expression of cytokines by T cells. 
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SPECIFIC AIMS 
During a pathogenic assault, the innate immune system relays information to the 
adaptive immune system to shape the immune response. Using cytokines as messengers, 
the innate immune system acts as the first line of defense against a pathogen and also 
activates long term defense systems. One way the innate immune system can do this is by 
steering the differentiation of activated CD4+ T cells into distinct Th cell lineages. By 
changing the phenotype of CD4+ T cells, the cytokines the Th cells express changes. This 
develops a more targeted defense against the infection.  
When infected by a virus, leukocytes will release a cytokine known as IFNα. 
IFNα belongs to an important family of cytokines known as Type I IFNs. When a cell’s 
IFNα/β receptor binds to IFNα, defense mechanisms activate that inhibit that cell from 
becoming infected with viruses. These defenses occur through an increase in expression 
of ISGs that promote an antiviral state in uninfected cells and decrease the viral 
replication cycle in cells that have already been infected with virus.  
Although IFNα is one of the first immune cytokines expressed during a viral 
infection, little is known about the influence that IFNα has on the expression of cytokines 
by activated CD4+ T cells. The first aim of this thesis is to evaluate IFNα’s effect on 
activated CD4+ T cells by evaluating their cytokine expression profiles in the presence or 
absence of IFNα treatment. The second aim is to determine if lack of Ikaros affects this 
response. 
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METHODS 
Mice 
The Ikaros conditional knockout mouse (Ikflox) was made by Dr. Susan Winandy together 
with the Mouse Biology Program at University of California, Davis. LoxP sites were 
placed to flank exon 7 and the 3’ untranslated region (UTR) of Ikzf1. The Ikflox mice 
(hereafter referred to as Cre- mice) were purchased from the Jackson laboratory and bred 
with an Lck distal promoter Cre transgenic mouse resulting in mice in which Ikaros is 
knocked out in mature T cells only. PCR analyses were used to determine genotypes of 
the mice which all had the C57BL/6 inbred genetic background. Both male and female 
mice were used with no difference seen in phenotype. All animal procedures were 
analyzed and approved by the Boston University Institutional Animal Care and Use 
Committee prior to beginning. (Lyon de Ana et al., 2019)  
Splenocyte preparation 
Spleens from 6 to 10-week-old mice were dissected utilizing aseptic techniques. Spleens 
were placed in petri dishes on ice with complete RPMI [GE Healthcare HyClone RPMI 
1640 medium supplemented with 10% fetal bovine serum (Atlanta Biologicals), 50μM β-
mercaptoethanol, 50μg/ml streptomycin, and 4mM L-glutamine]. Care was taken to 
remove most of the fatty tissue surrounding the spleens. To create single-cell 
suspensions, spleens were then ground between two frosted glass slides, and red cells 
were lysed using RBC lysis buffer (Santa Cruz). Cells were then washed twice with 
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complete RPMI, dyed with trypan blue and counted using a hemocytometer where the 
number of live cells was identified.  
CD4+ cell purification 
Splenocytes were resuspended in isolation buffer [phosphate-buffered saline (Fisher) 
with 0.1% bovine serum albumin (Fisher), and 23mM sodium citrate (EM Science)]. The 
cells were then pre-blocked with 2 μg/mL Fc block (anti-CD32/anti-CD16 from 
BioLegend) and rat serum (Sigma-Aldrich) for 30 minutes. The Dynabeads® 
FlowCompTM isolation kit (Invitrogen) was used to purify CD4+ T cells from 
splenocytes. Anti-CD4-biotin was added to the pre-blocked splenocytes, followed by a 
15-minute incubation with magnetic streptavidin-labeled beads at 4oC on a nutator. A 
magnet was used to isolate the CD4+ cells, which were bound to the beads. The beads 
were then resuspended in a release buffer and incubated for 10 minutes on a nutator, 
which freed the CD4+ cells from the beads. Beads were then removed from solution and 
discarded using a magnet. The purified CD4+ cells were then dyed with trypan blue and 
counted using a hemocytometer. 
T Cell Cultures 
Activating via TCR and IFNα simultaneously: A 24-well plate was coated with anti-CD3ε 
(145-2C11, Biolegend) by adding 200μL of 3 μg/mL anti-CD3ε in each well which was 
placed at 4oC the night before CD4+ cell purifications were performed. The following 
afternoon, the plate was washed with DPBS (GE Healthcare), and approximately 2x106 
purified CD4+ cells suspended in 2mL of complete RPMI were added to each well along 
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with 5 μg/mL soluble anti-CD28 (37.51, Bio-X-Cell). To half the wells, 100 U/mL of 
IFNα (Biolegend) also was added. Cells were incubated for 24 hours at 37oC. Then cells 
were harvested, and RNA was prepared as described below.  
Pre-treatment with IFNα Followed by TCR Activation: CD4+ T cells were purified from 
spleens as described above. In two wells, cells were plated at 3-5x106 cells per well 
suspended in 3.5mL of complete RPMI. To each well, 10 ng/ml IL-7 (Peprotech) was 
added to ensure cell viability and 100 U/mL of IFNα was added to one well. The cells 
were incubated at 37oC for 24 hours, after which they were plated in 24-well plate that 
had been coated with αCD3ε as described above. To each well, 5 μg/mL of αCD28 also 
was added and the cells were placed at 37oC. Following 24 hours, cells were harvested, 
and RNA was prepared as described below. 
Removal of IL-7 and IFNα from solution 
In one experiment, an additional plating strategy was used. CD4+ T cells were treated as 
described in the subsection Pre-treatment with IFNα followed by TCR Activation but 
following the 24-hour incubation, the cells were spun out of media and placed in fresh 
complete RPMI without cytokines before plating them with αCD3 and αCD28. Help with 
these experiments was provided by Ksenia Arakacheeva. 
RNA Isolation and cDNA Synthesis 
Total RNA from the cells was isolated using the RNeasy mini kit (Qiagen). Briefly, cells 
were resuspended in RLT buffer with β-mercaptoethanol, placed into a Qiashredder 
column (Qiagen), and centrifuged. Nucleic acids were then precipitated using 70% 
ethanol and placed into a spin column. The precipitate was then washed to remove 
 18 
impurities, followed by elution of the RNA from the spin column using Nuclease-free 
water. The concentration of RNA was determined using a Nanodrop 2000c (Thermo 
Scientific). Once the concentration of RNA was known, cDNA was prepared using a 
MaximaH protocol (Thermo Scientific).  
Quantitative real-time PCR (qRT-PCR) 
qRT-PCR was performed using SSO-Advanced Universal SYBR Green Supermix 
(BioRad) on a BioRad MyiQ Real-Time PCR machine. The data gathered was analyzed 
using the Pfaffl method to normalize the target gene data with a reference gene, HPRT. 
Primers used were generated by IDT DNA technologies.  
Table 1: Table of qRT-PCR Primers 
Primer Sequence 
CD25 Forward GCCACGCTTGCTGATGTT 
CD25 Reverse GGATGGTGCCGTTCTTGTAGG 
GM-CSF Forward ATGCCTGTCACGTTGAATGAAG 
GM-CSF Reverse GCGGGTCTGCACACATGTTA 
HPRT Forward GGATATGCCCTTGACTATATTGAG 
HPRT Reverse GCCACAGGACTAGAACACC 
IFITM3 Forward CTGCTGCCTGGGCTTCATAG 
IFITM3 Reverse GGATGCTGAGGACCAAGGTG 
IFNγ Forward ACAATGAACGCTACACATTGC 
IFNγ Reverse CTTCCACATCTATGCCACTTGAG 
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Ikaros (exon 7) Forward TCTACCTAACCAACCACATCAAC 
Ikaros (exon 7) Reverse TGCTGACCACACGGAAGG 
IL-2 Forward TGAGCAGGATGGAGAATTACAGG 
IL-2 Reverse GTCCAAGTTCATCTTCTAGGCAC 
IL-4 Forward AACTCCATGCTTGAAGAACTC 
IL-4 Reverse CCAGGAAGTCTTTCAGTGATGTG 
TNFα Forward TTCTGTCTACTGAACTTCGG 
TNFα Reverse ACTTGGTGGTTTGCTACG 
 
Statistics 
Statistical analyses were performed using unpaired two-tailed Student t tests.   
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RESULTS  
Effect of Pre-exposure to IFNα on Expression of Cytokines by Activated CD4+ T 
cells 
We first asked if pre-treatment with IFNα would affect the cytokine response in 
CD4+ T cells upon TCR activation. To answer this question, we treated wild type (Cre-) 
CD4+ T cells with IFNα overnight and compared their responses upon activation to cells 
that we did not treat with IFNα. To keep cells viable during the overnight incubation, 
they were also treated with IL-7. The following day, all cells had their TCRs activated 
overnight with αCD3/αCD28. These experiments were labelled as sets 2, 4, 5 and 7. 
In order to ensure the IFNα treatment worked, we measured expression of the ISG 
Interferon-induced transmembrane protein 3 (Ifitm3) which codes for the ifitm3 protein. 
Ifitm3 is part of a family of proteins that inhibit infection of cells with enveloped viruses 
by inhibiting the viruses’ entry and fusion from late endosomes. The gene that codes for 
Ifitm3 is induced by type I interferons and help the cells protect themselves from viral 
infections. Mice lacking Ifitm3 expression showed significantly increased vulnerability to 
viruses such as West Nile Virus (Gorman, Poddar, Farzan, & Diamond, 2016). The 
expression of Ifitm3 in Cre- cells treated with IFNα (IFNα+) was significantly increased 
(Fig 3). This showed that our IFNα treatment was successful.  
We next asked if IFNα pre-treatment would affect activation of CD4+ T cells. 
CD25 or IL-2Rα is tightly regulated at the transcriptional level and only expressed upon 
TCR activation. By testing for expression of the gene encoding CD25, Il2ra, it is possible 
to test if CD4+ T cell activation is affected by pre-treatment with IFNα. There was no 
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significant change between IFNα+ and IFNα- groups in expression of the gene encoding 
CD25 indicating that the activation of CD4+ T cells treated with IFNα was normal (Fig 
3). 
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Figure 3: Expression of genes Il2ra and Ifitm3 in Cre- CD4+ T cells treated with or 
without IFNα prior to activation. 
 
cDNA made from mRNA of CD4+ T cells from mice with the Cre- genotype when 
treated or not treated with IFNα was used to analyze the gene expression of Il2ra and 
Ifitm3 by qRT-PCR. Values were first normalized to HPRT and then to expression in 
IFNα- cultures (making IFNα- culture equivalent to “1”). Each graph shows the results of 
four independent experiments per graph using the same activation method with one 
exception being the set 5 Cre- IFNα- Fresh Media whose cells were spun out of media 
containing IFNα prior to TCR activation.  
a: p=0.2975, n=4. b: **p=0.0024, n=4. (statistics exclude set 5 Cre- IFNα- Fresh Media) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
** 
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The next thing we tested for was if cytokine expression was altered by the IFNα 
treatment. We looked at expression of some key pro-inflammatory cytokines expressed 
by CD4+ T cells. We found that the gene expression of two genes, Ifng the gene encoding 
the protein IFNγ and Il2 the gene that encodes for IL-2, were affected by pre-treatment 
with IFNα.  
Ifng expression was significantly lower whereas Il2 expression was significantly 
higher in the IFNα+ group compared to the IFNα- group (Fig 4). Next, we looked at other 
pro-inflammatory cytokines expressed by CD4+ T cells upon TCR activation including 
the gene encoding for GM-CSF, CSF2; the gene encoding for IL-4, Il4; and the gene 
encoding for TNFα, TNF. We found that the expression of these genes was not 
significantly affected by IFNα treatment (Fig 4). This shows that only certain cytokines’ 
genes are affected by IFNα treatment. The CSF2 expression levels did appear to be 
trending downwards with IFNα treatment, but more biological replicates must be 
performed to see if there is a significant change. We also looked at the expression levels 
of the gene encoding for the Ikaros protein, Ikzf1, to see if they are affected by IFNα 
treatment and saw that there was a significantly higher expression of Ikaros in cells pre-
treated with IFNα (Fig 4). 
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Figure 4: Expression of genes Ifng, Il2, and Ikzf1 in Cre- CD4+ T cells treated with 
or without IFNα prior to activation. 
 
cDNA made from mRNA of CD4+ T cells from mice with the Cre- genotype when 
treated or not treated with IFNα prior to activation was used to analyze the expression of 
genes encoding Ifng, Il2, and Ikzf1 by qRT-PCR. Primers that amplified exon 7 of the 
Ikaros gene were used when evaluating Ikaros gene expression. Values were first 
normalized to HPRT and then to expression in IFNα- cultures (making IFNα- cultures 
equivalent to “1”). Each graph shows the results of four independent experiments per 
graph. 
a: *p= 0.0403, n=4. b: **p=0.0033, n=4. c: **p=0.0069, n=4. (statistics exclude set 5 
Cre- Fresh Media) 
 
 
* 
** 
** 
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 Figure 5: Expression of genes CSF2, Il4, and TNF in Cre- CD4+ T cells treated with 
or without IFNα prior to activation. 
 
cDNA made from mRNA of CD4+ T cells from mice with the Cre- genotype when 
treated or not treated with IFNα was used to analyze the gene expression of CSF2, Il4 and 
TNF by qRT-PCR. Values were first normalized to HPRT and then to expression in 
IFNα- cultures (making IFNα- cultures equivalent to “1”). Each graph shows the results 
of four independent experiments per graph. 
a: p= 0.4712, n=4. b: p=0.6571, n=4. c: p=0.3204, n=4. (statistics exclude set 5 Cre- 
Fresh Media) 
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Interestingly, when cells were spun out of the media that contains IFNα prior to 
TCR activation as was done for set 5 Fresh Media Cre-, some IFNα effects of IFNα on 
cytokine expression were lost and, in some instances, enhanced. Expression of the gene 
Il2ra appeared to be trending upwards with IFNα treatment which was not seen when the 
media containing IFNα was not spun out (Fig 3). Levels of expression of Ifng and Il2 in 
the IFNα+ cells showed similar trends observed previously with Il2 expression enhanced 
and Ifng expression decreased (Fig 4). Levels of Tnf and Csf2 were also decreased, in 
each case to lower levels than observed in any of the cultures in which IFNα-containing 
media was not removed prior to activation (Fig 5). Il4 levels could not be detected in set 
5 Fresh Media Cre- in either the IFNα+ or IFNα- cells indicating its expression was 
negligible (Fig 5).  
These data suggest that IFNα somehow imprints its effect on CD4+ T cells since 
cells do not need IFNα constantly to see an effect on cytokine expression. However, since 
this was only done once, biological replicates must be performed to have significant 
confidence in the results. 
Effect of exposure to IFNα at the time of activation on expression of cytokines by 
CD4+ T cells 
With the difference in cytokine expression seen with the pre-treatment with IFNα, 
we next asked if the same effect is seen when CD4+ T cells are activated and treated with 
IFNα simultaneously. These experiments were labelled sets 1, 3, 6, and 8. First, IFNα-
induced changes to the control genes encoding Ifitm3 and CD25 were examined to 
confirm that the IFNα treatment induced ISGs and to determine if it affected TCR 
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activation, respectively. A significant increase in expression of the gene encoding Ifitm3 
was observed in all IFNα treated cells indicating that the IFNα treatment was effective 
(Fig 6). For the gene encoding CD25, there was no significant difference in expression 
between the IFNα+ and IFNα- cells (Fig 6). 
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Figure 6: Expression of genes Ifitm3 and Il2ra in Cre- CD4+ T cells treated with or 
without IFNα prior to activation. 
 
cDNA made from mRNA of CD4+ T cells from mice with the Cre- genotype when 
treated or not treated with IFNα was used to analyze the gene expression of Ifitm3 and 
Il2ra by qRT-PCR. Values were first normalized to HPRT and then to expression in 
IFNα- cultures (making IFNα- cultures equivalent to “1”). Each graph shows the results 
of four independent experiments per graph.  
a: *p=0.0138, n=4. b: p=0.2386, n=4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
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Next, we tested Il2 and Ifng expression levels to see if the significant differences 
in expression observed with IFNα pre-treatment were also observed with the 
simultaneous treatment. There were no significant differences in either Il2 or Ifng gene 
expression between IFNα+ and IFNα- cells (Fig 8). This could indicate that cytokine 
expression can only be altered when conditions are met with appropriate timing of IFNα-
exposure which would depend on the microenvironment around the cells at the time of 
their activation. However, there was a significant decrease in Csf2 levels (Fig 7). For all 
other genes tested, including Ifng, Il2, Ikzf1, Il4, and TNF, there were no significant 
differences in gene expression between IFNα+ cells and IFNα- cells (Fig 8).  
In conclusion, with these experiments, we were able to show that there was no 
effect of IFNα on CD4+ T cell activation in either of the two groups, but there was a 
differential effect on cytokine gene expression depending on whether there was pre-
treatment with IFNα or treatment with IFNα at the time of TCR activation.  
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Figure 7: Expression of gene CSF2 in Cre- CD4+ T cells treated with or without 
IFNα simultaneously to activation. 
 
cDNA made from mRNA of CD4+ T cells from mice with the Cre- genotype when 
treated or not treated with IFNα was used to analyze the gene expression of gene CSF2. 
Values were first normalized to HPRT and then to expression in IFNα- cultures (making 
IFNα- culture equivalent to “1”). The graph shows the results of four independent 
experiments.  
*p=0.03394, n=4. 
 
* 
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Figure 8: Expression of genes Ifng, Il4, Il2, TNF, and Ikzf1 in Cre- CD4+ T cells 
treated with or without IFNα simultaneously to activation. 
 
cDNA made from mRNA of CD4+ T cells from mice with the Cre- genotype when 
treated or not treated with IFNα was used to analyze the gene expression of genes Ifng, 
Il4, Il2, TNF, and Ikzf1 by qRT-PCR. Primers that amplified exon 7 of the Ikaros gene 
were used when evaluating Ikaros gene expression. Values were first normalized to 
HPRT and then to expression in IFNα- cultures (making IFNα- cultures equivalent to 
“1”). Each graph shows the results of four independent experiments per graph.  
a: p=0.3939, n=4. b: p=0.1534, n=4. c: p=0.4151, n=4. d: p=0.6589, n=4. e: p=0.4553, 
n=4. 
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Effect of pre-exposure to IFNα on expression of cytokines by activated Ikaros-
deficient CD4+ T cells 
 
In resting CD4+ T cells, Ikaros is a repressor of the gene program associated with 
the response to type I IFNs (Lyon de Ana et al., 2019). Lack of Ikaros causes an increase 
in inflammatory cytokine expression in CD4+ T cells at the earliest stages of TCR 
activation, with increased expression of the genes encoding IFNγ, TNFα, GM-CSF, and 
IL-2 (Lyon de Ana, 2019). Ikaros-deficient CD4+ T cells also show increased expression 
of type I ISGs. This suggests that Ikaros may modulate both the type I IFN-induced 
pathway and the pro-inflammatory cytokine pathway. We wanted to ask if Ikaros 
modulates the crosstalk between these two pathways and, therefore, if lack of Ikaros 
would alter the effects seen with IFNα treatment. So, next, we activated Cre+ CD4+ T 
cells, which lack Ikaros expression, and investigated their cytokine gene expression 
compared to the wild type (Cre-) cells. 
First, we used the IFNα pre-treatment method. We assayed IFNα-induced changes 
to the control genes which encode Ifitm3 and CD25, to see if IFNα induced ISGs or 
affected TCR activation, respectively. We saw a significant increase in expression of the 
gene encoding Ifitm3 in all the IFNα treated cells indicating that the IFNα treatment was 
effective (Fig 9). There was a significantly higher expression of the gene encoding CD25 
with IFNα treatment (Fig 9). This indicates that in mature T cells lacking Ikaros, IFNα 
pre-treatment may enhance TCR activation. 
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Figure 9: Expression of genes Ifitm3 and Il2Ra in Cre+ CD4+ T cells treated with or 
without IFNα prior to activation. 
 
cDNA made from mRNA of CD4+ T cells from mice with the Cre+ genotype when 
treated or not treated with IFNα was used to analyze the gene expression of genes Ifitm3 
and Il2Ra by qRT-PCR. Values were first normalized to HPRT and then to expression in 
IFNα- cultures (making IFNα- cultures equivalent to “1”). Each graph shows the results 
of four independent experiments per graph.  
a: ***p=0.0007, n=4. b: ***p=0.0004, n=4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*** *** 
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Next, we wanted to ask if pro-inflammatory cytokine gene expression was also 
affected differently in the Cre+ IFNα pre-treated cells compared to what was observed 
with pre-treatment of wild type Cre- cells. First, we tested the expression of Il2 and Ifng 
since their expression was significantly changed with IFNα pre-treatment in wild type 
Cre- cells. There was no significant difference seen in Il2 expression, but there was again 
a significantly lower expression of Ifng in the IFNα+ cells (Fig 10).  
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Figure 10: Expression of genes Il2 and Ifng in Cre+ CD4+ T cells treated with or 
without IFNα prior to activation. 
 
cDNA made from mRNA of CD4+ T cells from mice with the Cre+ genotype when 
treated or not treated with IFNα was used to analyze the gene expression of genes Ifitm3 
and Il2Ra by qRT-PCR. Values were first normalized to HPRT and then to expression in 
IFNα- cultures (making IFNα- cultures equivalent to “1”). Each graph shows the results 
of four independent experiments per graph.  
a: p=0.6480, n=4. b: *p=0.0375, n=4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
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We then examined expression of all other cytokine genes whose expression was 
tested in the wild type Cre- cells and found that there was similarly no significant change 
in expression of Il4, TNF, or CSF2 (Fig 11).  
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Figure 11: Expression of genes Il4, TNF, and GM-CSF in Cre+ CD4+ T cells treated 
with or without IFNα prior to activation. 
 
cDNA made from mRNA of CD4+ T cells from mice with the Cre+ genotype when 
treated or not treated with IFNα was used to analyze the gene expression of genes Il4, 
TNF, and GM-CSF by qRT-PCR. Values were first normalized to HPRT and then to 
expression in IFNα- cultures (making IFNα- culture equivalent to “1”). Each graph shows 
the results of four independent experiments per graph.  
a: p=0.9544, n=4. b: p=0.1632, n=4. c. p=0.5635, n=4.  
 
 
 
 
 
 
 
 
 
 
 
 
 38 
Effect of exposure to IFNα at the time of activation on expression of cytokines by 
Ikaros-deficient CD4+ T cells 
Next, we tested the effects of treatment with IFN at the same time as TCR 
activation in the Cre+ CD4+ T cells. We saw a significant increase in expression of the 
gene encoding Ifitm3 in IFNα treated cells indicating that the IFNα treatment was 
effective (Fig 12). There was no significant increase in expression of the gene encoding 
CD25 with IFNα treatment though it did appear to be trending upwards (Fig 12). 
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Figure 12: Expression of genes Ifitm3 and Il2ra in Cre+ CD4+ T cells treated with or 
without IFNα simultaneously to activation. 
 
cDNA made from mRNA of CD4+ T cells from mice with the Cre+ genotype when 
treated or not treated with IFNα was used to analyze the gene expression of genes Ifitm3 
and Il2ra by qRT-PCR. Values were first normalized to HPRT and then to expression in 
IFNα- cultures (making IFNα- cultures equivalent to “1”). Each graph shows the results 
of four independent experiments per graph.  
a: **p=0.0077, n=4. b: p=0.1741, n=4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
** 
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In contrast to what was observed for wild type Cre- cells, there was no significant 
decrease in CSF2 gene expression suggesting that lack of Ikaros blocks this effect (Fig 
13). 
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Figure 13: Expression of gene CSF2 in Cre+ CD4+ T cells treated with or without 
IFNα prior to activation. 
 
cDNA made from mRNA of CD4+ T cells from mice with the Cre+ genotype when 
treated or not treated with IFNα was used to analyze the gene expression of gene CSF2 
by qRT-PCR. Values were first normalized to HPRT and then to expression in IFNα- 
cultures (making IFNα- cultures equivalent to “1”). The graph shows the results of four 
independent experiments.  
p=0.3206, n=4.  
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We then examined the expression of all other cytokine genes tested in the wild 
type Cre- cells and found that there was no significant change in expression of Il2, Il4, 
TNF, or Ifng (Fig 14). Taken together, these results suggest that lack of Ikaros does 
influence the effect of IFN on cytokine gene expression in CD4+ T cells since the 
results of the Cre+ cells differ from those of the Cre- cells. 
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Figure 14: Expression of genes Il2, Il4, TNF, and Ifng in Cre+ CD4+ T cells treated 
with or without IFNα prior to activation. 
 
cDNA made from mRNA of CD4+ T cells from mice with the Cre+ genotype when 
treated or not treated with IFNα was used to analyze the gene expression of genes Il2, Il4, 
TNF, and Ifng by qRT-PCR. Values were first normalized to HPRT and then to 
expression in IFNα- cultures (making IFNα- culture equivalent to “1”). Each graph shows 
the results of four independent experiments per graph.  
a: p=0.1268, n=4. b: p=0.1641, n=4. c: p=0.6857, n=4. d: p=0.1880, n=4.  
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DISCUSSION 
 The goal of this study was to evaluate the effect of IFNα treatment on 
inflammatory cytokine expression in CD4+ T cells. Two protocols that altered timing of 
exposure of CD4+ T cells to IFN, either prior to or during TCR activation, were utilized 
to examine the impact of IFN on cytokine expression. The results provided an insight 
into mechanisms that could contribute to the suppression of immune responses observed 
in chronic viral infections.  
Some events following TCR/co-receptor stimulation can occur rapidly in a CD4+ 
T cell, whereas other events may take longer to occur. NF-κΒ and NFAT are transcription 
factors that act quickly since they are located in the T cell's cytosol where they can be 
activated via removal of an inhibitor protein or via phosphorylation, respectively. Once 
active, these transcription factors travel to the nucleus and where they alter gene 
expression. If nuclear translocation of these transcription factors is inhibited, the TCR/co-
receptor signal is unable to induce cytokine expression (Feske, Draeger, Peter, Eichmann, 
& Rao, 2000). If IFNα treatment causes changes in activation of transcription factors, this 
could be an explanation for some of the altered cytokine expression levels seen with 
IFNα treatment including the decrease in Ifng and CSF2. Epigenetic changes, such as 
chromatin remodeling, histone modifications and DNA methylation, which affect 
accessibility of genes, could take longer to occur. The interplay between these two 
methods of transcriptional regulation could explain the differences in cytokine gene 
expression seen between cell sets treated with IFN for different timeframes utilized. 
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For example, pre-treatment of cells overnight with IFNα before TCR/co-receptor 
activation, would allow time for epigenetic changes to occur. This could explain why a 
significant expression difference was observed looking at changes in gene expression of 
Ifng and Il2, which was not observed when cells were treated with IFNα at the time of 
TCR/co-receptor activation. 
With chronic viral infection, there is a suppression of the immune response. If 
there is a continued viral infection, the immune system does not clear virus as well due to 
this suppression. Since viruses induce expression of type I IFNs like IFNα, and type I 
IFNs decrease expression of Ifng in CD4+ T cells, this could be a partial explanation for 
the immune suppression seen in chronic viral infections. Increased Ifng expression leads 
to increased IFNγ levels released by CD4+ T cells that can serve as a signal to increase 
activity of CTLs, which play a key role in fighting viral infections. 
My studies have shown that pre-treatment with IFNα increases expression of Il2 
by CD4+ T cells. Increased expression of Il2 could stimulate proliferation of Tregs 
further suppressing the immune response in viral infection (Nelson, 2004). The high 
expression of Il2 induced by pre-treatment with IFN could explain the dichotomous 
behavior of type I IFNs in infections. Type I IFNs play roles in both immune system 
activation and suppression. IL-2 plays similar roles by allowing development of Tregs to 
suppress immune activation, while also contributing to protective immunity via 
interactions with CTLs and promoting T helper cell survival. 
Treatment of Cre- CD4+ T cells with IFN at the time of TCR/co-receptor 
activation resulted in a significant reduction in Csf2 expression levels while other 
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cytokine genes tested did not show significantly different levels of expression. This 
decrease was not observed when cells were pre-treated with IFN prior to activation, 
showing that timing of IFNα exposure relative to activation signals can result in different 
impacts to cytokine gene expression.   
Ikaros and the IFNα Pathway 
 CD4+ T cells that lack Ikaros show increased expression of the inflammatory 
cytokines IFNγ, TNFα, GM-CSF, and IL-2 (Lyon de Ana et al., 2019). These cells also 
showed increased expression of ISGs such as IFNα (Lyon de Ana et al., 2019). To test if 
Ikaros had a role to play in the crosstalk between the IFNα pathway and the pro-
inflammatory cytokine expression pathway, the cytokine gene expression levels of Cre+ 
and wild type Cre- CD4 T cells treated with IFN were compared   
 When Cre+ CD4+ T cells were pre-treated with IFNα followed by TCR/co-
receptor activation the increased expression of Il2 with IFNα treatment was lost, but the 
decreased expression of Ifng was retained. When Cre+ CD4+ T cells were treated with 
IFN at the time of TCR/co-receptor activation the significant decrease in CSF2 
expression that was found in Cre- cells no longer occurred. These results could mean that 
Ikaros plays a role in the activation of transcription factors or in inducing epigenetic 
changes to allow IFNα to have its effect on pro-inflammatory cytokine expression. 
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